Abstract
BackgroundVarious biomarkers have been investigated for their ability to identify patients more likely to respond to immunotherapy. Recently, the PD-1 inhibitor pembrolizumab was approved by the FDA for treating patients...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have